Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

223 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No evidence of autoimmune disorders in antiretroviral-experienced HIV-1-infected individuals after long-term treatment with raltegravir.
Baroncelli S, Mezzaroma I, Fantauzzi A, Galluzzo CM, Antoni AD, Vullo V, Francisci D, Ladisa N, Vivarelli A, Cirioni O, Sighinolfi L, Weimer LE, Fragola V, Fidanza R, Cara A, Palmisano L. Baroncelli S, et al. Among authors: cirioni o. Antivir Ther. 2013;18(3):321-7. doi: 10.3851/IMP2433. Epub 2012 Oct 9. Antivir Ther. 2013. PMID: 23047152
Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.
Baroncelli S, Pirillo MF, Galluzzo CM, Antoni AD, Ladisa N, Francisci D, d'Ettorre G, Segala D, Vivarelli A, Sozio F, Cirioni O, Weimer LE, Fragola V, Parruti G, Floridia M. Baroncelli S, et al. Among authors: cirioni o. AIDS Res Hum Retroviruses. 2015 Jan;31(1):71-7. doi: 10.1089/AID.2014.0060. AIDS Res Hum Retroviruses. 2015. PMID: 25092266 Free PMC article.
HIV-1 DNA dynamics and variations in HIV-1 DNA protease and reverse transcriptase sequences in multidrug-resistant patients during successful raltegravir-based therapy.
Michelini Z, Galluzzo CM, Pirillo MF, Francisci D, Degli Antoni A, Vivarelli A, Ladisa N, Cirioni O, Weimer LE, Fragola V, Cara A, Floridia M, Baroncelli S. Michelini Z, et al. Among authors: cirioni o. J Med Virol. 2016 Dec;88(12):2115-2124. doi: 10.1002/jmv.24581. Epub 2016 May 30. J Med Virol. 2016. PMID: 27197719
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection.
Weimer LE, Fragola V, Floridia M, Guaraldi G, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Parruti G, Giacometti A, Manconi PE, Vivarelli A, D'Ettorre G, Mura MS, Cicalini S, Preziosi R, Sighinolfi L, Verucchi G, Libertone R, Tavio M, Sarmati L, Bucciardini R; ISS-NIA Study Group. Weimer LE, et al. J Antimicrob Chemother. 2013 Jan;68(1):193-9. doi: 10.1093/jac/dks341. Epub 2012 Sep 14. J Antimicrob Chemother. 2013. PMID: 22984206 Free PMC article.
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors.
Bucciardini R, D'Ettorre G, Baroncelli S, Ceccarelli G, Parruti G, Weimer LE, Fragola V, Galluzzo CM, Pirillo MF, Lucattini S, Bellagamba R, Francisci D, Ladisa N, Degli Antoni A, Guaraldi G, Manconi PE, Vullo V, Preziosi R, Cirioni O, Verucchi G, Floridia M; ISS-NIA study group. Bucciardini R, et al. Among authors: cirioni o. Int J STD AIDS. 2012 Jul;23(7):459-63. doi: 10.1258/ijsa.2012.011391. Int J STD AIDS. 2012. PMID: 22843997 Clinical Trial.
Interindividual and intra-individual variabilities of darunavir and ritonavir plasma trough concentrations in multidrug experienced HIV patients receiving salvage regimens.
Baroncelli S, Villani P, Galluzzo CM, Cavalli A, Volpe A, Francisci D, Vivarelli A, Sozio F, Tedeschi S, Cirioni O, Sighinolfi L, Cusato M, Pirillo MF, Weimer LE, Fragola V, Parruti G, Regazzi M, Floridia M. Baroncelli S, et al. Among authors: cirioni o. Ther Drug Monit. 2013 Dec;35(6):785-90. doi: 10.1097/FTD.0b013e31829ad690. Ther Drug Monit. 2013. PMID: 24061444
Relationship between health-related quality of life measures and high HIV viral load in HIV-infected triple-class-experienced patients.
Bucciardini R, Pugliese K, Weimer L, Digregorio M, Fragola V, Mancini M, Maroccia Z, Ladisa N, Francisci D, Bellagamba R, Degli Antoni A, Guaraldi G, Cirioni O, Ortu F, Parruti G, Mannazzu M, Libertone R, Donnini S, Floridia M; ISS-NIA Study Group. Bucciardini R, et al. Among authors: cirioni o. HIV Clin Trials. 2014 Jul-Aug;15(4):176-83. doi: 10.1310/hct1504-176. HIV Clin Trials. 2014. PMID: 25143026
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report.
Cirioni O, Weimer LE, Fragola V, Giacometti A, Gabrielli E, Marchionni E, Massella M, Barchiesi F. Cirioni O, et al. West Indian Med J. 2013;62(4):377-9. doi: 10.7727/wimj.2011.193. West Indian Med J. 2013. PMID: 24756601
A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation.
Cirioni O, Weimer LE, Fragola V, Giacometti A, Ancarani F, Maracci M, Gabrielli E, Marchionni E, Pirillo MF, Vella S. Cirioni O, et al. West Indian Med J. 2014 Dec;63(7):779-84. doi: 10.7727/wimj.2013.264. Epub 2013 Sep 3. West Indian Med J. 2014. PMID: 25867565 Free PMC article.
223 results